Hyperbaric Oxygen and COVID-19

Clinical trials registered on clinicaltrials.gov
1. Hyperbaric Oxygen (HBO₂) Therapy as a Treatment for COVID-19 Infection
   (not yet recruiting) • (HBO₂ protocol not given)

**Sponsor:** Ochsner Health System, New Orleans, Louisiana ((NCT number): NCT04343183
Information provided by (Responsible Party)/PI: John Engle, Ochsner Health System

**STUDY DESCRIPTION**

**Brief Summary:** Patients who meet inclusion criteria will be randomized into treatment versus control group. Treatment groups will undergo hyperbaric oxygen (HBO₂) therapy (protocol not described) and compared to the control group.

**Detailed Description:** After enrollment, patients will be randomized into treatment versus control group. Both populations will receive the same inpatient medical treatment. All patients in the treatment group will undergo hyperbaric oxygen therapy under the same treatment protocol. After completion of the treatment protocol, specific study endpoints will be compared between the treatment and control groups.

**STUDY DESIGN**

<table>
<thead>
<tr>
<th>Study type</th>
<th>Interventional (Clinical Trial)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimated enrollment</td>
<td>48 participants</td>
</tr>
<tr>
<td>Allocation</td>
<td>Randomized</td>
</tr>
<tr>
<td>Intervention model</td>
<td>Parallel assignment</td>
</tr>
<tr>
<td>Intervention model description</td>
<td>This study will utilize a single-center sequential two-parallel-group (HBO₂/standard care) randomized controlled design with two looks to allow for early stop due to clear benefit/harm.</td>
</tr>
<tr>
<td>Masking</td>
<td>Single (Outcomes Assessor)</td>
</tr>
<tr>
<td>Masking description</td>
<td>The biostatistician and radiologist will be blinded.</td>
</tr>
<tr>
<td>Estimated study start date</td>
<td>April 2020</td>
</tr>
<tr>
<td>Estimated study completion date</td>
<td>June 2020</td>
</tr>
</tbody>
</table>

**OUTCOME MEASURES**

**Primary Outcome Measures**
1. Decrease incidence of intubation by 30% or greater [time frame: one month];
   Compare rates of intubation between treatment and control groups

**Secondary Outcome Measures**
1. Decrease renal injury [time frame: one month];
   Measure glomerular filtration rate (GFR) and compare between treatment and control groups

**ELIGIBILITY / INCLUSION CRITERIA**

1. adult inpatients >18 years old (all sexes)  
2. positive PCR COVID-19 testing  
3. CT evidence of interstitial lung opacity  
4. oxygen saturation <90% on room air  
5. pO₂ = 55-70

**EXCLUSION CRITERIA**

1. increased oxygen requirements  
2. hemodynamic instability (MAP<65)  
3. bradycardia (HR <50)  
4. history of seizure disorder  
5. pneumothorax  
6. GFR <30  
7. hemodialysis  
8. refractory anxiety/claustrophobia  
9. current pregnancy  
10. Uncorrectable hypoglycemia

**CONTACTS**

- John F. Engle, MD • +985-768-8918 • englemdf94@gmail.com
- Michael D. Lindley, MD • +504-957-3326 • mdlindley@gmail.com
2. Hyperbaric Oxygen for COVID-19 Patients: NCT0433208
(Recruiting) • HBO₂ protocol as below • (HBO₂ 2.0 ATA 1-5 treatments)

Sponsors and Collaborators: NYU Langone Health; NYU Winthrop Hospital
Information provided by (Responsible Party): NYU Langone Health

STUDY DESCRIPTION

Brief Summary: Hyperbaric oxygen (HBO₂) therapy treatment will be provided to patients as an adjunct to standard therapy for a cohort of 40 COVID19-positive patients with respiratory distress at NYU Winthrop Hospital. All patients prior to the clinical application of HBO₂ will be evaluated by the primary care team and hyperbaric physician. After the intervention portion of this study a chart review will be performed to compare the outcomes of intervention patients versus patients who received standard of care.

Detailed Description: This is a single-center prospective pilot cohort study to evaluate the safety and efficacy of hyperbaric oxygen (HBO₂) therapy as an emergency investigational device for treating patients with a novel coronavirus disease, COVID-19. Patients who meet inclusion criteria will be consented by the hyperbaric physician. They will then be transported from the ED or other unit to the hyperbaric unit while maintaining airborne precautions based on the most current hospital protocol. All study personnel will have proper PPE at all times. The patient will then be placed into the monoplace chamber and when the chamber door is closed the patient will remove any respiratory filter/mask that was placed. The patient will receive 90 minutes of hyperbaric oxygen at 2.0 ATA with or without air breaks per the hyperbaric physician. Upon completion of the treatment the patient will then return to the medical unit and continue all standard of care. Additional treatments (up to 5) can be given if warranted and agreed upon by the patient and all members of the team caring for the patient. After the intervention portion of this study a chart review will be performed to compare the outcomes of intervention patients versus patients who received standard of care.

STUDY DESIGN • OUTCOME MEASURES

Primary Outcome Measures
1. Mortality [time frame: duration of hospitalization: 5-7 days on average]

Secondary Outcome Measures
1. Days on invasive mechanical ventilation [time frame: duration of hospitalization: 5-7 days on average]

ELIGIBILITY / INCLUSION CRITERIA
In order to be eligible to participate in this study an individual must meet all of the following criteria:
1. male or female, age >18 years
2. positive COVID-19 test
3. respiratory compromise defined by SpO₂ <93%
4. ability to sign informed consent

EXCLUSION CRITERIA
An individual who meets any of the following criteria will be excluded from participation in this study:
1. pregnancy
2. untreated pneumothorax

CONTACTS
• Scott Gorenstein • +516-663-8498 • Scott.Gorenstein@nyulangone.org
• David Lee • +212-562-6561 • David.Lee@nyulangone.org
3. Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With COVID-19: NCT04344431 (Recruiting)

**Sponsor:** Direction Centrale du Service de Santé des Armées

**STUDY DESCRIPTION**

**Brief Summary:** Several patients with hypoxaemic SARS-CoV-2 pneumonia were able to benefit from hyperbaric oxygen (HBO₂) treatment in China. In a clinical case published in the *Chinese Journal of Hyperbaric Medicine*, treatment with repeated HBO₂ sessions prevented admission to intensive care unit with mechanical ventilation in a patient aged 69 who presented with signs of respiratory decompensation. HBO₂ can dramatically increase the amount of dissolved oxygen in the blood. HBO₂ not only promotes blood transport but also its tissue delivery. Furthermore, HBO₂ has specific immunomodulatory properties, both humoral and cellular, making it possible, for example, to reduce the intensity of the inflammatory response and to stimulate antioxidant defenses by repeating sessions. A virucidal capacity of HBO₂ therapy might also be involved.

**Detailed Description:** The main objective of this study is to assess the effectiveness of HBO₂ in addition to normal management over the period of normalization of the oxygen requirement (oxygen dependence) in patients with SAR-CoV-2 pneumonia not requiring invasive or non-invasive ventilation. It is a prospective, interventional, multicenter, controlled, randomized study. Patients admitted for SARS-CoV2 pneumonia in the COVID sector of the hospital who have oxygen-dependence criteria will be proposed for inclusion in accordance with the inclusion and non-inclusion criteria. Randomization will be carried out to determine the allocation in two groups: an HBO₂ group which will perform a daily session after checking for the absence of contraindication to HBO₂ and a non-HBO₂ control group with the same clinical criteria, but who will not benefit from HBO₂ sessions. In both groups standard continuous treatment with normobaric oxygen will be maintained.

**STUDY DESIGN**

**Estimated enrollment** 100 participants

**Allocation** Randomized

**Intervention model** Parallel assignment

**Masking** Single (Outcomes Assessor)

**Primary purpose** Treatment

**Actual study start date** April 14, 2020

**Estimated primary completion date** April 2021

**Estimated study completion date** May 2021

**OUTCOME MEASURES**

**Primary Outcome Measures**

1. Time to normalize the oxygen requirement (oxygeno-dependence), i.e., allowing a pulse oximetry value in ambient air greater than or equal to 92% and / or arterial blood gas with a PaO₂ value greater than 60mmHg in ambient air

**Secondary Outcome Measures**

1. Days of hospitalization between the HBO₂ group and the control group
2. Number of days with oxygen need, taking into account the predictors of bad outcome
3. Oxygen flow values to obtain a saturation by pulse oximetry greater than or equal to 92% values between the HBO₂ group and the control group
4. Oxygen flow values to obtain a saturation by pulse oximetry greater than or equal to 92% between the HBO₂ group and the control group
5. Days on invasive mechanical ventilation
6. Mortality
ELIGIBILITY / INCLUSION CRITERIA
1. male or female, age ≥18 years
2. patient with oxygen dependence criterion: need to maintain an oxygen flow rate less than or equal to 6 liters / minute to obtain saturation by pulse oximetry (SpO₂) greater than or equal to 92% or arterial gas with value PaO₂ greater than 60mmHg
3. diagnostic confirmation of COVID-19 pneumonia

EXCLUSION CRITERIA
1. minor subject (age <18 years)
2. person unable to give consent
3. pregnancy
4. participating in another research
5. signs of respiratory decompensation requiring mechanical ventilation
6. diagnosis of pneumonia with SARS-CoV-2 not confirmed
7. oxygen dependence criterion exceeded, i.e., need to maintain an oxygen flow rate greater than or equal to 6 liters / minute to obtain saturation by pulse oximetry (SpO₂) greater than or equal to 92% or arterial gas with value of PaO₂ greater than 60mmHg
8. inability to maintain the prolonged sitting position (at least 2 hours)
9. subject with contraindications to HBO₂ therapy

CONTACT
• Jean-Eric Blatteau, MD, PhD • +483162189 ext +33 • Sainte Anne Military Teaching Hospital, Toulon, France
• jeaneric.blatteau@intraldef.gov.fr
4. Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19
(HBO₂ protocol 2.4 bar (2.4 ATA), 30 minutes (excluding compression/recompression-maximum 5 treatments over 7 days)

Karolinska University Hospital
Collaborators: Karolinska Institutet; University of California San Diego; Blekinge County Council Hospital

STUDY DESCRIPTION
Brief Summary: Mortality rates in patients who develop ARDS is extremely high, 61.5-90%, almost double the mortality of ARDS of any cause. ARDS associated with COVID-19 is associated with pulmonary edema, rapidly progressing respiratory failure and fibrosis. The mechanism behind the rapid progress is still an enigma, but theories have evolved around severe inflammatory involvement with a cytokine storm. HBO₂ significantly reduces inflammatory cytokines and edema.

Detailed Description: Mortality rates have been reported as high as 90% in patients developing ARDS in early reports and more recent reports have reported overall 28-day mortality rates of 61.5% in ICU patients with acute respiratory illness. ARDS associated with COVID-19 differs from other ARDS, with rapidly progressing respiratory failure and fibrosis. Macrophage activation is involved early and cytokine modulators such as interleukin-6 (IL-6) inhibitors have been tried in experimental settings but no proper clinical trials have proven positive outcome. Hyperbaric oxygen (HBO₂) significantly reduces inflammatory cytokines including IL-1β, IL-6 and TNF-α through several transcription factors regulating inflammation, including hypoxia inducible factor 1 (HIF-1), Nrf2 and NFkB.

STUDY DESIGN
Study type Intervenational (Clinical Trial)
Estimated enrollment 200 participants
Allocation Randomized
Intervention model Parallel Assignment
Intervention model description Randomized controlled, open label, multicenter
Masking None (Open-Label)
Primary purpose Treatment
Estimated study start date April 25, 2020
Estimated primary completion date October 31, 2021
Estimated study completion date December 31, 2022

PRIMARY OUTCOME MEASURES
1. PO₂/FiO₂ (safety) oxygen requirement (arterial blood gas (pO₂))
2. Fraction of inspired oxygen within 1 hour before and after HBO₂ and 6 hours after each HBO₂ treatment.
   PO₂/FiO₂ (efficacy)
3. Oxygen requirement (arterial blood gas (pO₂) and recorded fraction of inspired oxygen) At baseline, daily for 7 days, Day 14 and Day 30 (or last day in hospital if patient is discharged earlier or at withdrawal) irrespective of HBO₂ treatments.
4. National early warning score mean NEWS at baseline, within 1 hour before and after and 6 hours after HBO₂, daily for 7 days, Day 14 and Day 30 (or last day in hospital if patient is discharged earlier, or at withdrawal) irrespective of HBO₂ treatments.
5. Immunological response: Measurement baseline, daily for 7 days, Day 14, Day 30 (or last day in ICU if patient has left ICU earlier, or at withdrawal)
   a. Complete blood cell count including WBC count + differential
   b. C-reactive protein
   c. Procalcitonin
   d. Cytokines including but not limited to IL-6
6. Mechanical ventilation: Days free of invasive mechanical ventilation
SECONDARY OUTCOME MEASURES
1. Adverse events, including SAE – serious adverse events
2. Serious ADR – serious adverse drug reaction
3. Oxygen dose: Mean oxygen dose calculated as oxygen tolerance units (OTU)
4. Imaging, including pulmonary CT (low-dose CT), chest X-ray and chest ultrasound
5. Secondary infections
6. Mortality
7. ICU-free days
8. ICU mortality: Mortality for any cause in ICU (% of patients admitted to ICU)
9. Hospital mortality: Mortality of any cause in Hospital
11. Immunological response: Baseline, Day 3, Day 5, Day 7. In first 20 patients Cytokines extended, including (IL-1β, IL-2, IL-6, IL33 and TNFα). Lymphocyte profile flow cytometry with identification of monocyte/lymphocyte subsets including but not limited to CD3+/CD4+/CD8+ monocyte proliferation markers
12. Viral load (quantitative PCR) (Baseline, Day 7, Day 14, Day 30)

OTHER OUTCOME MEASURES
1. Staff safety – Serious and all adverse events in staff associated with treatment of COVID patients
2. HBO₂ feasibility
   a. Number of HBO₂ treatments given/planned first 10 days
   b. Received HBO₂ treatment within 24 hours of enrolment (Yes/No)

ELIGIBILITY / INCLUSION CRITERIA
1. age 18-90 years, both genders
2. patient meets ARDS criteria (Berlin definition) and needs intubation, ventilator-assisted or ECMO-assisted treatment within 7 days of admission to hospital
3. suspected or verified COVID-19 infection
4. at least one risk factor for increased mortality in COVID-19: currently published, e.g., smoking, hypertension, diabetes, cardiovascular disease
5. documented informed consent according to ICH-GCP and national regulations

EXCLUSION CRITERIA
1. ARDS with etiology other than COVID
2. known pregnancy or positive pregnancy test in women
3. patients with previous lung fibrosis
4. CT- or spirometry-verified severe COPD with emphysema
5. contraindication for HBO₂ according to local guidelines
6. do not resuscitate (DNR) or other restrictions in escalation of level of care

CONTACTS
• Anders Kjellberg, MD • +46812375212 • anders.kjellberg@ki.se
• Peter Lindholm, MD, PhD • peter.lindholm@ki.se
NCT04358926 (not yet recruiting) (HBO₂ protocol not specified; 8 sessions of HBO₂ vs. 8 sessions of normobaric O₂ in chamber over 4 days

**Sponsor:** Assaf-Harofeh Medical Center

Information provided by (Responsible Party): Assaf-Harofeh Medical Center

**STUDY DESCRIPTION**
The 2019-20 coronavirus disease caused by COVID-19 is an ongoing pandemic. So far no specific treatment has proven efficacy. Recent case series reported the use of hyperbaric oxygen (HBO₂) therapy on 5 severe COVID-19 patients who developed respiratory insufficiency. HBO₂ mechanisms of tissue oxygenation and anti-inflammatory effect may explain these findings. The purpose of the current study is the evaluate the efficacy of HBO₂ therapy in moderate-severe COVID-19 patients in a randomized controlled manner.

**STUDY DESIGN**

<table>
<thead>
<tr>
<th><strong>Study type</strong></th>
<th>Interventional (Clinical Trial)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Estimated enrollment</strong></td>
<td>30 participants</td>
</tr>
<tr>
<td><strong>Allocation</strong></td>
<td>Randomized</td>
</tr>
<tr>
<td><strong>Intervention model</strong></td>
<td>Parallel assignment</td>
</tr>
<tr>
<td><strong>Intervention model description</strong></td>
<td>Randomized controlled, double-blinded</td>
</tr>
<tr>
<td><strong>Masking</strong></td>
<td>Double (Participant, Outcomes Assessor)</td>
</tr>
</tbody>
</table>

**OUTCOME MEASURES**

**Primary Outcome Measures**

1. PaO₂/FiO₂: 1 day and 7 days after the last intervention session. Oxygenation index of the lungs calculated PaO₂ measured in the blood divided by the inhaled FiO₂.
2. SpO₂: One hour prior to and after every intervention session, 1 day and 7 days after the last intervention session. Oxygen saturation measured in %.
3. NEWS Score: One hour prior to and after every intervention session, 1 day and 7 days after the last intervention session national early warning score (NEWS) calculated by the patient's vitals and condition.
4. Inflammation level: 1 day and 7 days after the last intervention session including white blood cell count, CRP level, ESR and cytokines: IL-1, IL-2, IL-6, IL-10, TNF-α, procalcitonin, ferritin.

**Secondary Outcome Measures**

1. Symptoms level: 1 day and 7 days after the last intervention session. Patient’s reported symptoms including cough, dyspnea, etc.
2. Average oxygen supply per day: 1 day and 7 days after the last intervention. Oxygen amount supplied measured in IU.
3. Viral load: 1 day and 7 days after the last intervention session. Quantitative measurement of viral load in the blood using quantitative RT-PCR.
4. Chest X-ray changes: 1 day and 7 days after the last intervention session. Chest xray changes evaluated qualitatively and quantitatively.
5. Number of patients with IgG seroconversion: 1 day and 7 days after the last intervention session.
   Number of patients who developed SARS-CoV-2 IgG antibodies.
6. Number of patients with IgM seroconversion: 1 day and 7 days after the last intervention.
   Number of patients who developed SARS-CoV-2 IgM antibodies.
7. FEV1/FVC: 1 day and 7 days after the last intervention session. Pulmonary function tests performed bedside.
8. Time to symptoms recovery within 30 days. Measured time patient suffered symptoms until complete recovery.
9. Number of patients who required invasive ventilation within 30 days.
10. Time to negative virus PCR within 30 days. The measured time until the patient had two negative SARS-CoV-2 PCRs.
11. Mortality rate within 30 days.
12. Number of barotrauma events within 7 days after the last session.
13. The number of adverse events in each arm.

INCLUSION CRITERIA
1. adults (age 18 or older)
2. male and female
3. positive SARS-CoV-2 RT-PCR
4. at least one risk factor for bad prognosis of COVID-19: hypertension, diabetes mellitus, ischemic heart disease, smoking, age >50, etc.
5. respiratory insufficiency: room air \( \text{SpO}_2 < 94\% \) or \( \text{PaO}_2/\text{FiO}_2 < 300\text{mmHg} \)
6. ability to sign an informed consent

Exclusion Criteria
• negative SARS-CoV-2 RT-PCR
• HBO\(_2\) therapy contraindication: pneumothorax, pneumomediastinum, claustrophobia, ear/sinus disease, known chronic pulmonary disease such as severe emphysema or known pulmonary bullae.
• pregnancy
• inability to sign an informed consent

CONTACTS
• Amir Hadanny, MD • +972544707381 • amir.had@gmail.com
• Shai Efrati, MD • efratishai@outlook.com